Every 10-Q that Biocorrx Inc (BICX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BICX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BICX filings page.
BioCorRx Inc. reported continued losses and liquidity pressure for the three and six months ended June 30, 2026. Net sales were $87,970 for the quarter and $167,038 for the first half of 2026, down from $178,238 and $313,137 in the prior-year periods as Lucemyra supply and distribution sales softened.
The company recorded a first-half net loss of $2,012,798 (loss per share $0.07), slightly improved from $2,229,040 in 2025, helped by higher NIH grant income of $1,042,074. Research and development expenses more than doubled to $1,064,717, reflecting increased investment in BICX104 and related programs, while selling, general and administrative costs declined.
Liquidity remains strained: cash was $21,237 with a working capital deficit of $8,231,326 and total liabilities of $14,379,077 against total assets of $1,907,459. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern and plans to rely on additional debt and equity financing and NIH grants, including an $11,029,977 NIDA award for BICX104. Common shares outstanding increased to 29,758,177 as of August 14, 2026, driven by equity issuances, debt amendments, and related-party financings.
BioCorRx Inc. reported unaudited results for the three months ended March 31, 2026, showing a small increase in revenue but continued losses and tight liquidity. Net sales rose to $214,539 from $134,899, driven mainly by supply and distribution sales of Lucemyra, its opioid withdrawal treatment. The company also recognized $362,597 of grant income supporting development of its sustained-release naltrexone programs.
Operating expenses climbed to $1,170,539, including higher research and development spending of $352,333, resulting in a loss from operations of $956,000. Net loss attributable to BioCorRx was $831,227, or $(0.03) per basic and diluted share, slightly better than the prior-year loss of $841,407 and $(0.06) per share, helped by lower non-related-party interest expense.
Liquidity remains strained. Cash totaled only $211,911 with a working capital deficit of $7,506,752 and total liabilities of $13,948,134 against assets of $2,324,865. Management disclosed that these conditions raise “substantial doubt” about the company’s ability to continue as a going concern. To bridge its funding gap, BioCorRx relied on a $500,000 common stock subscription from its president, conversions and amendments of several promissory notes, and $85,904 of new related-party advances during the quarter.
BioCorRx (BICX) filed its Q3 2025 10‑Q, highlighting its first meaningful product revenue following the Lucemyra asset purchase. Supply and distribution sales reached $635,224 for the quarter and $946,572 year‑to‑date, driving total net sales of $948,362 for the nine months. The company recorded a Q3 net loss attributable to BioCorRx of $1,917,873 and a year‑to‑date loss of $3,992,701, reflecting higher operating expenses as the business scales.
Cash was $287,688 with a working capital deficit of $13,575,951, and management disclosed substantial doubt about the company’s ability to continue as a going concern. Total assets rose to $7,533,473, including intangible assets of $3,011,833 and goodwill of $2,840,400 tied to the US WorldMeds Lucemyra acquisition, while total liabilities were $20,297,768. The company recognized Q3 grant income of $867,130 under NIDA awards and reported a grant receivable of $761,515 and deferred grant revenue of $56,590. Operating expenses increased to $2,580,811 in Q3, including research and development of $1,004,660 and SG&A of $1,145,353, leading to a Q3 operating loss of $1,945,587.